| Literature DB >> 25943322 |
Sung Han Kim1, Kyung Min Kang2, Ami Yu2, Jung Hoon Lee3, Byung Ho Nam4, Eun Sik Lee3.
Abstract
PURPOSE: The objective of this study is to evaluate the relationship of atheroembolic risk factors with postoperative recovery of renal function after on-clamp partial nephrectomy (PN) with warm ischemia in patients with staged T1-2 renal cell carcinoma (RCC).Entities:
Keywords: Atherosclerosis; Creatinine; Embolism; Nephron sparing surgery; Renal cell carcinoma; Renal function
Mesh:
Substances:
Year: 2015 PMID: 25943322 PMCID: PMC4720065 DOI: 10.4143/crt.2014.297
Source DB: PubMed Journal: Cancer Res Treat ISSN: 1598-2998 Impact factor: 4.679
Baseline demographics of low- and high-risk atheroembolism groups
| Variable | Low-risk group (n=185, 79.0%) | High-risk group (n=49, 21.0%) | p-value |
|---|---|---|---|
| Male/Female | 131(70.8)/54(29.2) | 36(73.5)/14(26.5) | 0.853 |
| Age[ | 51.4±11.0 | 66.4±6.2 | < 0.001 |
| BMI[ | 24.4±3.0 | 24.9±3.3 | 0.421 |
| Follow-up[ | 61.3±17.0 | 57.3±16.6 | 0.136 |
| Number of risk factors of AE[ | 2.2±1.0 | 6.7±1.7 | < 0.001 |
| Smoking history | 31 (16.8) | 7 (14.3) | 0.829 |
| Anti-thromboembolic therapy | 3 (1.6) | 11 (22.4) | < 0.001 |
| Anticoagulation therapy | 10 (5.4) | 24 (49.0) | < 0.001 |
| Diabetes | 9 (4.9) | 18 (36.7) | < 0.001 |
| Hypertension | 28 (15.1) | 40 (81.6) | |
| Hypercholesterolemia | 0 | 7 (14.3) | |
| Atherosclerotic vascular disease | 1 (0.5) | 7 (14.3) | |
| ASA | |||
| Group 1 | 124 (67.0) | 10 (20.4) | < 0.001 |
| Group 2 | 60 (32.5) | 36 (73.5) | |
| Group 3 | 1 (0.5) | 3 (6.1) | |
| Baseline laboratory findings[ | |||
| Hemoglobin (g/dL) | 14.3±1.4 | 13.8±1.7 | 0.102 |
| ESR (mg/dL) | 14.8±19.7 | 26.1±39.4 | 0.484 |
| Albumin (g/dL) | 4.4±0.3 | 4.3±0.3 | 0.066 |
| Calcium (mg/dL) | 9.3±0.7 | 9.4±0.4 | 0.144 |
| Creatinine (mg/dL) | 1.0±0.2 | 1.0±0.2 | 0.242 |
| eGFR (mL/min/1.73 m2)[ | 77.8±16.4 | 71.7±14.7 | 0.017 |
| Last creatinine[ | 0.9±0.2 | 1.1±0.7 | 0.05 |
| Last eGFR[ | 81.2±16.7 | 69.3±19.6 | < 0.001 |
| Posteoperative CKD | 9 (4.9) | 6 (12.2) | 0.035 |
| Tumor size[ | 2.9±1.3 | 3.0±1.4 | 0.367 |
| R.E.N.A.L. nephrometry score | 7.0±2.4 | 8.0±1.8 | 0.119 |
| Pathologic T1 stage | 158 (85.4) | 37 (75.5) | 0.211 |
| T2 | 27 (16.6) | 30.2±10.2 | |
| Ischemic time[ | 28.3±11.3 | 30.2±10.2 | 0.277 |
| Operative time[ | 169.3±41.8 | 169.6±42.3 | 0.955 |
| Estimated blood loss[ | 249.6±189.1 | 268.8±172.5 | 0.513 |
| Safety margin[ | 3.0±2.0 | 2.7±2.1 | 0.326 |
Values are presented as number (%) or mean±standard deviation (SD). BMI, body mass index; AE, adverse effect; ASA, American Society of Anesthesiologists; ESR, erythrocyte sedimentation rate; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; MDRD, Modification of Diet in Renal Disease.
t test comparative analysis (mean±SD),
eGFR, estimated glomerular filtration rate calculated by MDRD equation.
Fig. 1.Mean creatinine (Cr) levels (A) and estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) equation (B) at the time of the postoperative follow-up of the high-risk and low-risk groups of atheroembolism are shown along with their comparative p-values for each follow-up month. sCr, serum creatinine; RF, risk factors.
Fig. 2.Postoperative changes in the mean creatinine (Cr) levels (A) and estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) equation (B) differences compared to the baseline values are shown along with the comparative p-values for each follow-up month between high- and low-risk groups of atheroembolism. sCr, serum creatinine; RF, risk factors.
Correlation analysis between atheroembolic risk and severities of postoperative renal functional change via serum creatinine and eGFR-MDRD
| Follow-up time | Response variable | Risk factor group | Mean estimated change | p-value | Odds ratio | 95% Confidence interval |
|---|---|---|---|---|---|---|
| 1 mo | Low risk | 1.00 (reference) | ||||
| Creatinine | High risk | -0.545 | 0.072 | 0.58 | 0.32-1.05 | |
| eGFR-MDRD | High risk | 0.449 | 0.169 | 1.566 | 0.827-2.965 | |
| 3 mo | Low risk | 1.00 (reference) | ||||
| Creatinine | High risk | -1.933 | 0.016 | 0.145 | 0.03-0.695 | |
| eGFR-MDRD | High risk | 1.305 | 0.103 | 3.689 | 0.768-17.71 | |
eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease.
Proportional odds model of postoperative serum creatinine and eGFR-MDRD change to their baseline values in relation to atheroembolic risks
| Follow-up time | Differential grouping d/t creatinine change | Mean estimated change | p-value | Odds ratio | 95% Confidence interval |
|---|---|---|---|---|---|
| Postoperative serum creatinine change | |||||
| 1 mo | 1 (diff < 0) | 1.00 (reference) | |||
| 2 (0 ≤ diff < 0.1) | -0.357 | 0.507 | 0.7 | 0.244-2.005 | |
| 3 (0.1 ≤ diff < 0.2) | 0.073 | 0.881 | 1.076 | 0.415-2.786 | |
| 4 (diff ≥ 0.2) | 0.651 | 0.153 | 1.918 | 0.786-4.680 | |
| 3 mo | 1 (diff < 0) | 1.00 (reference) | |||
| 2 (0 ≤ diff < 0.1) | 1.289 | 0.466 | 3.63 | 0.114-116.1 | |
| 3 (0.1 ≤ diff < 0.2) | 1.7 | 0.311 | 5.474 | 0.205-146.5 | |
| 4 (diff ≥ 0.2) | 2.699 | 0.094 | 14.875 | 0.631-350.4 | |
| Postoperative eGFR change | |||||
| 1 mo | 1 (diff < -16.8) | 0.726 | 0.128 | 2.067 | 0.812-5.261 |
| 2 (-16.8 ≤ diff < -7.6) | 0.516 | 0.295 | 1.676 | 0.637-4.405 | |
| 3 (-7.6 ≤ diff < 0) | 0.997 | 0.078 | 2.712 | 0.893-8.241 | |
| 4 (diff ≥ 0) | 1.00 (reference) | ||||
| 3 mo | 1 (diff < -16.8) | 1.836 | 0.103 | 6.273 | 0.692-56.88 |
| 2 (-16.8 ≤ diff < -7.6) | -0.796 | 0.656 | 0.451 | 0.014-15.02 | |
| 3 (-7.6 ≤ diff < 0) | 1.449 | 0.243 | 4.26 | 0.373-48.59 | |
| 4 (diff ≥ 0) | 1.00 (reference) | ||||
eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease.
Logistic regression analysis of risk factors for development of chronic kidney disease after partial nephrectomy with warm ischemia
| Risk factor | Univariate analysis | Multivariate Hazard | ||||
|---|---|---|---|---|---|---|
| p-value | Hazard ratio | 95% CI | p-value | ratio | 95% CI | |
| Pathologic T3a | 0.020 | 9.6 | 1.435-64.219 | 0.004 | 317.6 | 14.20-468.16 |
| Nuclear grade | 0.073 | 1.8 | 0.208-15.561 | - | - | - |
| Body mass index | 0.309 | 1.091 | 0.922-1.291 | - | - | - |
| Estimated blood loss | 0.444 | 1.001 | 0.998-1.004 | - | - | - |
| Ischemic time | 0.632 | 1.011 | 0.966-1.059 | - | - | - |
| Tumor size | 0.363 | 1.193 | 0.816-1.743 | - | - | - |
| Operative time | 0.020 | 1.016 | 1.002-1.029 | 0.214 | 1.013 | 0.993-1.037 |
| Age > 55 yr | 0.156 | 2.261 | 0.730-7.007 | - | - | - |
| Hypertension | 0.043 | 3.112 | 1.036-9.349 | 0.823 | 1.237 | 0.186-9.388 |
| Diabetes | 0.004 | 5.868 | 1.754-19.628 | 0.005 | 102.3 | 5.293-513.0 |
| Lipidemia, cholesterolemia | 0.368 | 2.769 | 0.301-25.487 | - | - | - |
| Aortic atherosclerosis | 0.401 | 2.208 | 0.677-7.2 | - | - | - |
| Reno-atherosclerosis | 0.628 | 1.702 | 0.197-14.666 | - | - | - |
| Smoking | 0.178 | 2.326 | 0.68-7.953 | - | - | - |
| Cardiovascular op. Hx | 0.044 | 5.967 | 1.046-34.025 | 0.019 | 195.8 | 3.275-200.2 |
| Anticoagulant Tx. | 0.200 | 2.9 | 0.57-14.757 | - | - | - |
| Female sex | 0.068 | 0.07 | 0.005-0.537 | 0.007 | 0.002 | 0.001-0.089 |
| Aspirin therapy | 0.500 | 1.586 | 0.415-6.058 | - | - | - |
| Statin therapy | 0.211 | 2.383 | 0.611-9.303 | - | - | - |
| R.E.N.A.L. nephrometry score | 0.838 | 1.025 | 0.81-1.297 | - | - | - |
| Atheroembolic risk ≥ 5 | 0.041 | 3.132 | 1.019-9.248 | 0.020 | 0.445 | 0.134-0.854 |
| Baseline eGFR | 0.002 | 0.882 | 0.814-0.956 | 0.004 | 0.753 | 0.547-0.899 |
CI, confidence interval; op. Hx, operation history; Tx., treatment; eGFR, estimated glomerular filtration rate.